Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
314.94
-7.70 (-2.39%)
At close: Jul 11, 2025, 4:00 PM
317.00
+2.06 (0.65%)
After-hours: Jul 11, 2025, 7:47 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,052,959
Profits / Employee
-$120,942
Market Cap
41.06B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALNY News
- 11 days ago - Alnylam Pharma Stock Outlook: Is ALNY Topping Out? - Benzinga
- 24 days ago - Alnylam Pharmaceuticals Names Garg R&D Chief - Market Watch
- 24 days ago - Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
- 4 weeks ago - Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 6 weeks ago - Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Alnylam Issues 2024 Corporate Responsibility Report - Business Wire
- 2 months ago - AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
- 2 months ago - Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire